Profile Image

Dr Nikki Verrills

Senior Lecturer

School of Biomedical Sciences and Pharmacy (Medical Biochemistry)

Honing in on her target

Dr Nikki Verrills' research into a key signalling switch in cancer cells could provide an important breakthrough in treatment.

Nikki Verrills in the laboratory 

As a young undergraduate studying science, Dr Nikki Verrills had intentions of transferring to medicine. Then, she discovered a passion for laboratory research and realised she could effectively fight disease on another front.

"In the end I have achieved the best of both worlds," the biochemist and cancer researcher points out. "I am still in the medical field helping patients by contributing to the development of better treatments but I am also able to pursue my interest in lab work, which I find fascinating."

Verrills has certainly found her niche. Since completing her PhD in 2005 she has worked largely full-time in academic research, collecting a clutch of early career awards, fellowships and major grants in recognition of her groundbreaking research into leukaemia and breast cancer. She studies the molecular pathways of cancer, identifying genes and proteins in cancer cells in order to make comparisons between normal cells and cancer cells. She also analyses differences between cancer cells that respond well to drug treatments and those that do not.

"If scientists can identify proteins that are different in cancerous cells, or in drug-resistant cells, then we can design drugs to target those differences – drugs that will specifically kill cancerous cells but not normal cells," she explains. "That is fundamental cancer research, but most cancer drugs work by turning off a particular protein, or inactivating it. What is novel about our work is that we have targeted a protein that needs to be switched back on."

That protein is phosphatase 2A, or PP2A, which comes from a class of proteins known as 'tumour suppressors'. Normally, they act as a stop signal to inhibit the growth of cancerous cells. In leukaemia cells, however, PP2A is inactive, so the cancer cells continue to proliferate.

In 2007, Verrills worked with collaborators in the United States to prove that the drug FTY720 could effectively switch PP2A on in patients with chronic myeloid leukaemia (CML) – therefore stopping the cancer's spread without affecting the body's healthy cells. This year she was awarded a $360,000 grant from the Cure Cancer Australia Foundation and Cancer Council NSW to apply that research to a different cancer, acute myeloid leukaemia (AML), which has a very poor survival rate.

"There is a real urgency to find new treatments for AML because the vast majority of patients are resistant to chemotherapy and will die of the disease," Verrills asserts. The grant will allow Verrills and her team to test FTY720 and other drugs in different sub-types of AML, and move their work from the laboratory into clinical trials.

"Another focus of our work is establishing exactly how these types of drugs work," she outlines. "We know the end result is that they increase activity of PP2A but we want to advance the knowledge in this field by finding out specifically how they do that. Also, we know from literature that this class of proteins is important in a lot of solid tumours, so it is likely that this research will be applicable to other cancers as well."

Verrills has received ongoing support from high-profile national cancer organisations and has forged collaborations with key research groups in Australia and internationally. She also works closely with colleagues in the University's Centres for Cancer and Chemical Biology and through her links with the Hunter Medical Research Institute (HMRI) has established important working relationships with cancer specialists and haematologists. Her articles are published in internationally prominent journals and she has been recognised with a Voiceless Eureka Prize for Research for her commitment to minimising the use of animals in laboratory work. 

Verrills' doctoral studies into chemotherapy resistance in childhood leukaemia led to a Peter Doherty Postdoctoral Fellowship from the National Health and Medical Research Council in 2006. In the same year she was the inaugural recipient of a Hunter Medical Research Foundation grant for young cancer researchers. She is currently supported by an Early Career Researcher Fellowship with the Cancer Institute of NSW.

Verrills gained exposure during her doctoral studies to cutting-edge scientific techniques used at the Australian Proteomic Analysis Facility, in Sydney, becoming one of the first researchers in the country to use Difference In-Gel Electrophoresis (DIGE). This technique allows simultaneous analysis of proteins in cancerous, non-cancerous and control cells and vastly improves the efficiency and accuracy of testing.

The scientist admits that work/life balance is an elusive concept given her demanding research career, two young daughters and family interest in a vineyard (in which her husband Michael De Iuliis, a fellow scientist, is chief winemaker). But she praises the support of the University of Newcastle, which has allowed her to maintain the momentum of her research while juggling life's other commitments.

"Not only has the University supported me but it has also shown a lot of confidence in me, which is critical for career advancement," Verrills acknowledges. "I have my own research group and I have reached the stage of being an independent researcher much earlier than I probably would have anywhere else."

Visit the Priority Research Centre for Cancer

Visit the Priority Research Centre for Chemical Biology

Visit the HMRI website

Nikki Verrills in the laboratory

Honing in on her target

Dr Nikki Verrills’ research into a key signalling switch in cancer cells could provide an important breakthrough in treatment.

Read more

Career Summary

Biography

Dr Verrills research interests centre on understanding the signalling pathways involved in cancer development, progression and resistance to chemotherapy induced cell death. Her research involves cell biology and biochemistry, translation into clinically relevant mouse models of disease, and analysis of primary patient samples. During her PhD studies Dr Verrills used powerful proteomics techniques, including being one of the first in Australia to use difference in-gel electrophoresis (DIGE) technology, to discover novel protein alterations that confer chemotherapy resistance in childhood leukaemia.

In postdoctoral studies Dr Verrills further applied her proteomics skills to the investigation of respiratory disease, and has identified clinical biomarkers for asthma and chronic obstructive pulmonary disease. These proteins are now targets for patent applications and ongoing investigations into the development of diagnostics and improved therapies. Her postdoctoral studies in respiratory disease led to an interest in signalling pathways, with particular interest in the multifunctional protein phosphatase, PP2A. This led her to establish a research group investigating the role of protein phosphatase 2A (PP2A) in cellular functions. Her group has discovered novel roles for PP2A in cellular function and disease, including myeloid leukaemias, melanoma and asthma, and demonstrated that PP2A activation is a potential strategy for improved therapies (e.g. senior author papers in Cancer Research and Cell Signalling, and co-authored papers in Nature Medicine, Journal of Clinical Investigation; J Biol Chem; BBA; Cell Death & Diff). She has developed a unique panel of PP2A molecular reagents (shRNA, overexpression constructs, antibodies, pharmacological activators/inhibitors), and established strategic collaborations which has enabled her to expand her investigations of PP2A into the study of breast cancer.

Her PhD was awarded from Macquarie University in 2005, for which she received a Vice-Chancellor’s Commendation for Excellence in Research. In 2006 Dr Verrills received a highly competitive NHMRC Peter Doherty Postdoctoral Fellowship. Through this fellowship she also received a scholarship to the Australian Academy of Science “Science at the Shine Dome” meeting. In 2006 she also became the inaugural recipient of the Hunter Medical Research Institute (HMRI) Competitive Research Fund for Early Career Researchers in Cancer. In 2010 Dr Verrills was appointed to an ongoing academic position (Lecturer) at the University of Newcastle, however in 2011 she was awarded a Cancer Institute NSW Early Career Research Development Award, and after deferring this for a year for maternity leave, she took up this fellowship in Dec 2011.

Research outputs: Dr Verrills has 28 research publications, with 13 as first or senior author, appearing in journals of good to high impact in the field (average IF 6.4) and are well cited (>800 to date; average 59 cites/yr; h-index 14). The importance of her work has also been featured in editorial articles (Fojo, T (2006) J Natl Cancer Inst 98: 1363 and Ojima and Ferlini (2003) Chem Biol 10: 583).

Funding: Since 2006 Dr Verrills has attracted >$3M in competitive research grant/fellowship funding, from the NHMRC, Cancer Council NSW, Anthony Rothe Foundation, Ramaciotti Foundation, Cancer Institute NSW, Cure Cancer Australia Foundation, and the Hunter Medical Research Institute (HMRI). She has also attracted infrastructure funding from the ARC, ACRF, Ramaciotti Foundation and the Cancer Institute NSW of > $6.4M.

Awards: Dr Verrills research is internationally competitive and recognised through continued publications, presentations at international and national meetings, and international and national awards. These include the 2012 Newcastle Innovations ‘Rising Star Award’; 2010 HUPO Young Guns Award; 2007 Voiceless Eureka Prize; the 2007 Young Tall Poppy Award; the 2007 University of Newcastle Vice Chancellor’s Award for Research Excellence; 2004 Biochemical Journal Young Investigator Award, presented to the best young researcher at the 12th International Conference on Second Messengers and Phosphoproteins, Montreal, Canada; the Merck Sharp Dohm “Best of the Best” Award and the Cure Cancer Australia Foundation Award, both presented at the 2004 Australian Health and Medical Research (ASMR) Congress. In 2003 Dr Verrills was awarded the University of Sydney Medal for Excellence in Medical Research, presented to the best young researcher at the ASMR NSW Conference, and was a finalist in the Cure Cancer Australia Foundation’s Young Researcher of the Year Award.

Service to the discipline: Her expertise in the field of proteomics and cancer biology results in invitations to peer review grant applications (e.g. NHMRC, ARC, Wellcome Trust; AICR; Cure Cancer Australia Foundation), ~20 manuscripts/year for a variety of journals (e.g. Blood, Oncogene, Cancer Research; Molecular Cancer Therapeutics; Proteomics), and ~2 PhD theses/year. In 2012 and 2013 Dr Verrills was a panel member for the NHMRC Cancer Biology & Oncology grant review panel. She has also served on the Leukaemia Foundation PhD and Postdoctoral fellowship review panels. Dr Verrills is a mentor in a University run mentoring program for early career researchers, and has given many lectures to undergraduate, graduate, and school students on careers in medical research.

Invited presentations: In 2012 Dr Verrills was an invited speaker at the International meetings: Phophatases in Disease, Vic; 37th Annual Lorne Proteins Meeting, Vic; Garvan Signalling Meeting, Sydney; Australian Society for Medical Research (ASMR) NSW Branch Scientific Meeting, Sydney. She was also session chair for the ASMR NSW Branch Scientific Meeting and the New Directions in Leukaemia Research, Sunshine Coast. She regularly presents her research to other universities and research institutes. For example, in 2012 she presented at the Lowy Cancer Centre, UNSW, in 2010 at IMVS, Adelaide, and at Pharmaxis in Sydney. In past years she has presented at Macquarie University, The Oncology Research Unit, Westmead, and the Children’s Cancer Institute Australia, Sydney.

Student Supervision: Dr Verrills has been primary supervisor for 3 PhD students to completion, and a further student recently submitted. These students received a number of awards during their studies. She has supervised four Honours students (all received 1st Class).

Conference coordination: Dr Verrills was co-convenor for the international meeting: HMRI Translational Cancer Conference – Pathways to Tailored Therapies, Newcastle, 2008, and was on the organising committee for the 2006 HMRI Conference on Translational Cancer Research and again for the 2013 Conference.

Committees: Dr Verrills is an active member of the Hunter Medical Research Institute Cancer Research Program Steering committee, where she has taken a major role in building up the activities of the program including preparing strategic plans, infrastructure and program funding applications, inviting speakers and establishing an annual research seminar day to foster internal research collaborations. She is also a member of the University of Newcastle’s Australian Biomolecular Research Facility steering committee.

Community engagement: She has a strong commitment to the advancement and promotion of medical research in our society. As part of her community involvement she has disseminated her research through the print, radio, and television media, and has presented her research to the local community as a guest speaker at Rotary and Lions Clubs, and HMRI, Cure Cancer Australia, and Cancer Council NSW charity events. Through the Tall Poppy Campaign she has also presented her research to High School students across NSW, and has established relationships with her local school communities to foster and encourage an interest in studying science.

Current position: In Dec 2011 Dr Verrills returned from maternity leave as a Research Only Academic at the University of Newcastle, working 0.6FTE, funded by a Cancer Institute NSW ECR Development Award.

Research Expertise
Dr Verrills research interests centre on understanding the molecular changes involved in cancer progression and chemotherapy resistance. By using powerful proteomics techniques, including being one of the first in Australia to use difference in-gel electrophoresis (DIGE) technology, she has discovered novel protein alterations that confer chemotherapy resistance in childhood leukaemia. These proteins are now targets for ongoing investigations to develop improved therapies for relapsed leukaemia patients. Dr Verrills is currently investigating the role of the signaling protein, protein phosphatase 2A, in cancer. Using shRNA and overexpression transfection of normal and cancer cell lines, coupled with molecular and biochemical analyses such as PCR, immunoblotting, immunoprecipitation, immunofluorescence, 2D-DIGE and mass spectrometry, she is determining the role of mutant PP2A and specific PP2A subunits in the development of leukaemia and breast cancer.

Teaching Expertise
Dr Verrills is a strong supporter of fostering research students. She has supervised two Honours student (both received 1st Class), and is currently supervising one Honours and three PhD students. Dr Verrills is a fulltime research academic, however she does guest lecture for 2nd and 3rd year BBiomed Sci courses in Proteomics, Bioinformatics, Cancer, and Drug Resistance.

Administrative Expertise
Dr Verrills undetakes many administrative tasks, including managing the budgets for her grants. Some duties include obtaining product quotes, ordering, safety and ethics applications, co-ordinating multi investigator grant applications, and organising research seminar series and workshops.



Qualifications

  • Bachelor of Science (Honours), Macquarie University

Keywords

  • Breast Cancer
  • Cancer
  • Chemotherapy resistance
  • Drug resistance
  • Leukaemia
  • Protein phosphatase 2A
  • Proteomics
  • Signal transduction

Fields of Research

Code Description Percentage
060199 Biochemistry and Cell Biology not elsewhere classified 75
111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified 15
111299 Oncology and Carcinogenesis not elsewhere classified 10

Professional Experience

UON Appointment

Title Organisation / Department
Senior Lecturer University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Academic appointment

Dates Title Organisation / Department
21/05/2015 - 21/06/2015 Postdoctoral Scientist University of Newcastle
Australia
1/01/2012 - 31/12/2013 Membership - NHMRC Grant Review Panel NHMRC Grant Review Panel
Australia
1/01/2011 -  Fellow University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/01/2011 -  Cancer Institute NSW ECD Research Fellow Family Action Centre University of Newcastle
Australia
1/01/2006 - 1/07/2010 Peter Doherty Biomedical Fellow

NHMRC - Early Career Fellowships (Formerly Postdoctoral Training Fellowships)

National Health & Medical Research Council
1/01/2001 -  Membership - Australian Society for Medical Research Australian Society for Medical Research (ASMR)
Australia
1/01/1999 - 2/01/2001 Research Assistant Macquarie University
Australia

Membership

Dates Title Organisation / Department
Organising Committee Member - HMRI Conference on Translational Cancer Research Hunter Medical Research Institute (HMRI)
Australia
Committee Member - HMRI Cancer Research Group Steering Committee Hunter Medical Research Institute (HMRI)
Australia
Member - American Association of Cancer Research American Association of Cancer Research
United States

Awards

Honours

Year Award
1998 Bill Cantwell prize for Excellence in Biology
Macquarie University

Recipient

Year Award
2003 Australian Proteome Analysis Facility Scholarship 2001-2003
Australian Proteome Analysis Facility
2003 Australian Postgraduate Award 2001-2003
Macquarie University

Recognition

Year Award
2005 2005 - Doctor of Philosophy, Vice Chancellor Commendation.
Macquarie University
2003 2003 - Cure Cancer Australia Foundation's Young Researcher of the Year Award - Finalist.
Cure Cancer Australia Foundation

Research Award

Year Award
2004 Biochemical Journal Young Investigator Award - 12th International Conference on Second Messengers and Phosphoproteins
The Biochemical Journal
2004 2004 - Merck Sharp Dohm 'Best of the Best' Award - Australian Health and Medical Research Congress
Australian Society of Medical Research
2004 2004 - Cure Cancer Australia Foundation Award
Cure Cancer Australia Foundation
2003 2003 - University of Sydney Medal for Excellence in Medical Research
Australian Society of Medical Research

Invitations

Participant

Year Title / Rationale
2003 Protemics for cancer research
Organisation: Oncology Research Unit, Childrens Hospital, Westmead.
2003 Proteome analyses reveals novel mechanisms of resistance to anticancer agents.
Organisation: Oncology Research Unit, Childrens Hospital, Westmead.
2003 Amersham Biosciences Technical Seminar Series. Brisbane; Adelaide; Melbourne; Sydney.
Organisation: GE Biosciences Description: Amersham Biosciences, now part of GE Healthcare, is a world leader in proteomics technology. I was invited as an expert presenter on the use of state of the art proteomic technology, 2D difference gel electrophoresis, and how this technology can be applied in biomedical research.
2002 New technologies meets functional proteomics.
Organisation: ComBio 2002 Description: This was a special session at the ComBio meeting convened bythe Australian Proteomics Society and was an invited speaker.
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (1 outputs)

Year Citation Altmetrics Link
2011 Smith AM, Roberts KG, Verrills NM, 'Ser/Thr phosphatases: The new frontier for myeloid leukemia therapy?', Myeloid Leukemia - Basic Mechanisms of Leukemogenesis, Intech, Croatia 123-148 (2011) [B1]

Journal article (31 outputs)

Year Citation Altmetrics Link
2014 Goldie BJ, Dun MD, Lin M, Smith ND, Verrills NM, Dayas CV, Cairns MJ, 'Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons.', Nucleic Acids Research, 42 9195-9208 (2014) [C1]
DOI 10.1093/nar/gku594
Citations Scopus - 5Web of Science - 3
Co-authors Minjie Lin, Murray Cairns, Matt Dun, Christopher Dayas
2014 Hatchwell L, Girkin J, Morten M, Collison A, Mattes J, Foster PS, et al., 'Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease¿by modulating protein phosphatase 2A', Journal of Allergy and Clinical Immunology, (2014) [C1]

Background: ß-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinnin... [more]

Background: ß-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinning mechanisms remain poorly understood. Recently, a direct interaction between formoterol and protein phosphatase 2A (PP2A) has been described in¿vitro. Objective: We sought to elucidate the molecular mechanisms by which ß-agonists exert anti-inflammatory effects in allergen-driven and rhinovirus 1B-exacerbated allergic airways disease (AAD). Methods: Mice were sensitized and then challenged with house dust mite to induce AAD while receiving treatment with salmeterol, formoterol, or salbutamol. Mice were also infected with rhinovirus 1B to exacerbate lung inflammation and therapeutically administered salmeterol, dexamethasone, or the PP2A-activating drug (S)-2-amino-4-(4-[heptyloxy]phenyl)-2-methylbutan-1-ol (AAL[S]). Results: Systemic or intranasal administration of salmeterol protected against the development of allergen- and rhinovirus-induced airway hyperreactivity and decreased eosinophil recruitment to the lungs as effectively as dexamethasone. Formoterol and salbutamol also showed anti-inflammatory properties. Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signal-regulated kinase 1 and active nuclear factor ¿B subunits in the lungs. The anti-inflammatory effect of salmeterol was blocked by targeting the catalytic subunit of PP2A with small RNA interference. Conversely, increasing PP2A activity with AAL(S) abolished rhinovirus-induced airway hyperreactivity, eosinophil influx, and CCL11, CCL20, and CXCL2 expression. Salmeterol also directly activated immunoprecipitated PP2A in¿vitro isolated from human airway epithelial cells. Conclusions: Salmeterol exerts anti-inflammatory effects by increasing PP2A activity in AAD and rhinovirus-induced lung inflammation, which might potentially account for some of its clinical benefits. © 2013 American Academy of Allergy, Asthma & Immunology.

DOI 10.1016/j.jaci.2013.11.014
Citations Scopus - 5Web of Science - 4
Co-authors Paul Foster, Matt Dun, Joerg Mattes
2014 Hoffman A, Carpenter H, Kahl R, Watt LF, Dickson PW, Rostas JAP, et al., 'Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition', Cellular Signalling, 26 748-756 (2014) [C1]

Calcium/calmodulin-stimulated protein kinase II (CaMKII) is a multi-functional serine/threonine protein kinase that controls a range of cellular functions, including proliferation... [more]

Calcium/calmodulin-stimulated protein kinase II (CaMKII) is a multi-functional serine/threonine protein kinase that controls a range of cellular functions, including proliferation. The biological properties of CaMKII are regulated by multi-site phosphorylation and targeting via interactions with specific proteins. To investigate the role specific CaMKII phosphorylation sites play in controlling cell proliferation and cell cycle progression, we examined phosphorylation of CaMKII at two sites (T253 and T286) at various stages of the cell cycle, and also examined the effects of overexpression of wild-type (WT), T286D phosphomimic, T253D phosphomimic and T253V phosphonull forms of CaMKIIa in MDA-MB-231 breast cancer and SHSY5Y neuroblastoma cells on cellular proliferation and cell cycle progression. We demonstrate herein that whilst there is no change in total CaMKII expression or T286 phosphorylation throughout the cell cycle, a marked dephosphorylation of CaMKII at T253 occurs during the G2 and/or M phases. Additionally, we show by molecular inhibition, as well as pharmacological activation, that protein phosphatase 2A (PP2A) is the phosphatase responsible for this dephosphorylation. Furthermore, we show that inducible overexpression of WT, T286D and T253V forms of CaMKIIa in MDA-MB-231 and SHSY5Y cells increases cellular proliferation, with no alteration in cell cycle profiles. By contrast, overexpression of a T253D phosphomimic form of CaMKIIa significantly decreases proliferation, and cells accumulate in mitosis, specifically in metaphase. Taken together, these results strongly suggest that the dephosphorylation of CaMKII at T253 is involved in controlling the cell cycle, specifically the metaphase-anaphase transition. © 2014 Elsevier Inc.

DOI 10.1016/j.cellsig.2013.12.015
Citations Scopus - 2Web of Science - 1
Co-authors John Rostas, Kathryn Skelding, Phil Dickson
2013 Collison AM, Hatchwell LM, Verrills NM, Wark PA, Pereira De Siqueira AL, Tooze MK, et al., 'The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity', Nature Medicine, 19 232-237 (2013) [C1]
Citations Scopus - 32Web of Science - 28
Co-authors Joerg Mattes, Nathan Bartlett, Peter Wark, Paul Foster
2012 Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253', JOURNAL OF NEUROCHEMISTRY, 123 31-31 (2012) [E3]
Co-authors Kathryn Skelding, John Rostas, Phil Dickson
2012 Bradbury P, Mahmassani M, Zhong J, Turner K, Paul A, Verrills NM, O'Neill GM, 'PP2A phosphatase suppresses function of the mesenchymal invasion regulator NEDD9', Biochimica Et Biophysica Acta-Molecular Cell Research, 1823 290-297 (2012) [C1]
Citations Scopus - 8Web of Science - 6
2012 Tay KH, Jin L, Tseng HY, Jiang CC, Ye Y, Thorne RF, et al., 'Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress', Cell Death and Disease, 3 e337 (2012) [C1]
Citations Scopus - 15Web of Science - 15
Co-authors Xu Zhang, Rick Thorne
2011 Skelding KA, Rostas JA, Verrills NM, 'Controlling the cell cycle: The role of calcium/calmodulin-stimulated protein kinases I and II', Cell Cycle, 10 631-639 (2011) [C1]
DOI 10.4161/cc.10.4.14798
Citations Scopus - 27Web of Science - 29
Co-authors John Rostas, Kathryn Skelding
2011 Roberts KG, McDougall FK, Verrills NM, 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers - Response', Cancer Research, 71 2404-2404 (2011) [C3]
DOI 10.1158/0008-5472.can-10-4297
2011 Chang H-Y, Jennings PC, Stewart JL, Verrills NM, Jones KT, 'Essential role of protein phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by okadaic acid, dominant negative protein phosphatase 2A, and FTY720', Journal of Biological Chemistry, 286 14705-14712 (2011) [C1]
DOI 10.1074/jbc.M110.193227
Citations Scopus - 19Web of Science - 18
Co-authors Keith Jones
2011 Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, et al., 'Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, 183 1633-1643 (2011) [C1]
DOI 10.1164/rccm.201010-1623OC
Citations Scopus - 36Web of Science - 34
Co-authors Alistair Sim, Peter Gibson, Lisa Wood, Jodie Simpson, Vanessa Mcdonald
2010 Roberts KG, Smith AM, McDougall FK, Carpenter HC, Horan MP, Neviani P, et al., 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers', Cancer Research, 70 5438-5447 (2010) [C1]
DOI 10.1158/0008-5472.CAN-09-2544
Citations Scopus - 56Web of Science - 52
Co-authors Leonie Ashman, Alistair Sim
2010 Kranias G, Watt L, Carpenter HC, Holst J, Ludowyke R, Strack S, et al., 'Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation', Cellular Signalling, 22 1882-1890 (2010) [C1]
DOI 10.1016/j.cellsig.2010.07.017
Citations Scopus - 5Web of Science - 5
Co-authors Alistair Sim
2010 Skelding KA, Suzuki T, Gordon SL, Xue J, Verrills NM, Dickson PW, Rostas JA, 'Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function', Cellular Signalling, 22 759-769 (2010) [C1]
DOI 10.1016/j.cellsig.2009.12.011
Citations Scopus - 9Web of Science - 9
Co-authors John Rostas, Phil Dickson, Kathryn Skelding
2008 Ong V, Liem NLM, Schmid MA, Verrills NM, Papa RA, Marshall GM, et al., 'A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts', JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 324 434-442 (2008) [C1]
DOI 10.1124/jpet.107.128926
Citations Scopus - 12Web of Science - 12
2007 Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al., 'FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia', Journal of Clinical Investigation, 117 2408-2421 (2007) [C1]
DOI 10.1172/jci31095
Citations Scopus - 185Web of Science - 181
2006 Verrills NM, Po'Uha ST, Liu MLM, Liaw TYE, Larsen MR, Ivery MT, et al., 'Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia', Journal of the National Cancer Institute, 98 1363-1374 (2006) [C1]
DOI 10.1093/jnci/djj372
Citations Scopus - 44Web of Science - 40
2006 Verrills NM, 'Clinical proteomics: present and future prospects', Clinical Biochemist Reviews, 27 99-116 (2006) [C2]
2006 Sim AT, Ludowyke RI, Verrills NM, 'Mast cell function: Regulation of degranulation by serine/threonine phosphatases', Pharmacology & Therapeutics, 112 425-439 (2006) [C1]
DOI 10.1016/j.pharmthera.2006.04.011
Citations Scopus - 17Web of Science - 16
Co-authors Alistair Sim
2006 Verrills NM, Liem NL, Liaw TYE, Hood BD, Lock RB, Kavallaris M, 'Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study', Proteomics, 6 1681-1694 (2006) [C1]
DOI 10.1002/pmic.200500417
Citations Scopus - 61Web of Science - 57
2005 Kavallaris M, Verrills NM, 'Improving the targeting of tubulin-binding agents: lessons from drug resistance studies', Current Pharmaceutical Design, 11 1719-1733 (2005) [C1]
DOI 10.2174/1381612053764706
Citations Scopus - 43Web of Science - 43
2005 Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu MR, O''Neil GM, et al., 'Tissue-specific tropomyosin isoform composition', Journal of Histochemistry and Cytochemistry: imaging the spectrum of cell biology, 53 557-570 (2005) [C1]
DOI 10.1369/jhc.4A6505.2005
Citations Scopus - 65Web of Science - 63
2004 Don S, Verrills NM, Liaw TY, Liu ML, Norris MD, Haber M, Kavallaris M, 'Neuronal-associated microtubule proteins class III ß-tubulin ad MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs', Molecular Cancer Therapeutics, 3 1137-1146 (2004) [C1]
Citations Scopus - 35Web of Science - 32
2003 Verrills NM, Kavallaris M, 'Drug resistance mechanisms in cancer cells: A proteomics perspective', Current Opinion in Molecular Therapeutics, 5 258-265 (2003) [C1]
Citations Scopus - 20Web of Science - 20
2003 Mackintosh JA, Choi HY, Bae SH, Veal DA, Bell PJ, Ferrari BC, et al., 'A fluorescent natural product for ultra sensitive detection of proteins in one-dimensional and two-dimensional gel electrophoresis', Proteomics, 3 2273-2288 (2003) [C1]
DOI 10.1002/pmic.200300578
Citations Scopus - 95Web of Science - 89
2003 Verrills NM, Walsh BJ, Cobon GS, Hains PG, Kavallaris M, 'Proteome analysis of Vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations', Journal of Biological Chemistry, 278 4508-4509 (2003) [C1]
DOI 10.1074/jbc.M303378200
Citations Scopus - 59Web of Science - 55
2003 Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, et al., 'Microtubule alterations and mutations induced by desoxyepothilone B: Implications for drug-target interactions', Chemistry and Biology, 10 597-607 (2003) [C1]
DOI 10.1016/S1074-5521(03)00141-8
Citations Scopus - 90Web of Science - 85
2001 Kavallaris M, Verrills NM, Hill BT, 'Anticancer therapy with novel tubulin-interacting drugs', DRUG RESISTANCE UPDATES 4 (6): 392-401 DEC 2001, 392-401 (2001) [C1]
Citations Scopus - 88Web of Science - 79
2000 Verrills NM, Harry JH, Walsh BJ, Hains PG, Robinson ES, 'Cross-matching marsupial proteins with eutherian mammal databases: Proteome analysis of cells from UV-induced skin tumours of an opossum (Monodelphis domestica)', ELECTROPHORESIS 21 (17): 3810-3822 NOV 2000, 3810-3822 (2000) [C1]
Citations Scopus - 12Web of Science - 13
2000 Cordwell SJ, Nouwens AS, Verrills NM, Basseal DJ, Walsh BJ, 'Subproteomics based upon protein cellular location and relative solubilities in conjunction with composite two-dimensional electrophoresis gels', ELECTROPHORESIS 21 (6): 1094-1103 APR 2000, 1094-1103 (2000) [C1]
Citations Scopus - 109Web of Science - 100
1999 Cordwell SJ, Nouwens AS, Verrills NM, McPherson JC, Hains PG, Van Dyk DD, Walsh BJ, 'The microbial proteome database - an automated laboratory catalogue for monitoring protein expression in bacteria', ELECTROPHORESIS 20 (18): 3580-3588 DEC 1999, 3580-3588 (1999) [C1]
Citations Scopus - 16Web of Science - 17
Show 28 more journal articles

Conference (25 outputs)

Year Citation Altmetrics Link
2014 Delforce SJ, Pringle KG, Wang Y, Verrills NM, Scott RJ, Lumbers ER, 'THE FUNCTIONAL ROLE OF THE ENDOMETRIAL RENIN ANGIOTENSIN SYSTEM IN ENDOMETRIAL CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Rodney Scott, Kirsty Pringle
2014 Yoon E-J, Chi MN, Enjeti AK, Verrills NM, Skelding KA, 'CHARACTERISING A NEW TARGET FOR THE TREATMENT OF ACUTE LEUKAEMIAS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Kathryn Skelding
2014 Dun MD, Kahl RGS, Flanagan H, Cairns MMJ, Smith ND, Enjeti AK, et al., 'IDENTIFICATION OF ONCOGENIC SIGNALLING PATHWAYS IN ACUTE MYELOID LEUKAEMIA (AML) PATIENTS BY PHOSPHOPROTEOMICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Murray Cairns, Matt Dun
2014 De Iuliis GN, Verrills NM, Dun MD, 'IN SILICO ANALYSIS OF THE TARGETS OF SMALL-MOLECULE, ANTI-CANCER COMPOUNDS FOR IMPROVED CANCER THERAPEUTICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Matt Dun, Geoffry DeiuliIs
2013 Dun MD, Smith AM, Kahl RGS, Smith ND, Khanna A, Don AS, et al., 'Unraveling the mechanism of action: drugs that activate the tumor suppressor 2A.', CANCER RESEARCH, Washington, DC (2013) [E3]
DOI 10.1158/1538-7445.AM2013-2038
Co-authors Matt Dun
2012 Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Dephosphorylation of CAMKII at T253 controls progression through metaphase', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
Co-authors Phil Dickson, John Rostas, Kathryn Skelding
2011 Collison AM, Hatchwell LM, Pereira De Siqueira AL, Don A, Verrills NM, Foster PS, Mattes J, 'The development of house dust mite-induced allergic airways disease is regulated by a novel E3 ubiquitin ligase-dependent deactivation of a protein phosphatase', Respirology, Perth, WA (2011) [E3]
Co-authors Paul Foster, Joerg Mattes
2011 Hatchwell LM, Collison AM, Pereira De Siqueira AL, Foster PS, Verrills NM, Don A, et al., 'A novel E3 ubiquitin ligase links rhinovirus infection to exacerbation of asthma', Respirology, Perth, WA (2011) [E3]
Co-authors Joerg Mattes, Paul Foster, Peter Wark
2010 Irwin J, Verrills NM, He XY, Powell H, Wood LG, Gibson PG, 'Proteomic biomarkers as novel clinical diagnostics for airway disease', Abstract Book. Human Proteome World Congress Sydney 2010, Sydney, NSW (2010) [E3]
Co-authors Peter Gibson, Lisa Wood
2010 Verrills NM, Roberts KG, Smith AM, McDougall FK, Carpenter HC, Neviani P, et al., 'Targeting the tumour suppressor, PP2A, as a novel therapy for acute myeloid leukaemia', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
Co-authors Alistair Sim, Leonie Ashman
2010 Gilan O, Jastrezebski K, Diesch J, Verrills NM, Hannan RD, Dhillon AS, 'Functional regulation of the Fra-1/AP-1 Transcription factor via interactions with protein phosphatase 2A', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology. Poster Abstracts, Melbourne, Australia (2010) [E3]
2010 Skelding KA, Verrills NM, Dickson PW, Rostas JA, 'Regulation of proliferation of neuroblastoma cells by CaMKII', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
Co-authors Phil Dickson, Kathryn Skelding, John Rostas
2010 Skelding KA, Xue J, Suzuki T, Verrills NM, Dickson PW, Rostas JA, 'Mechanisms of phosphorylation-sensitive CaMKII targeting', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
Co-authors Phil Dickson, Kathryn Skelding, John Rostas
2009 Kranias G, Cottrell LF, Carpenter HC, Sim AT, Verrills NM, 'Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation', FEBS Journal, Prague, Czech Republic (2009) [E3]
Co-authors Alistair Sim
2009 Skelding KA, Liao X, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Functional consequences of CaMKII phosphorylation at THR253 in neurons', ANS 2009 Abstracts: Posters, Canberra, ACT (2009) [E3]
Co-authors Kathryn Skelding, John Rostas, Phil Dickson, Alistair Sim
2009 Rostas JA, Skelding KA, Liao X, Verrills NM, Dickson PW, 'Regulation of CaMKII by targeting', Proceedings of the 2nd Australia-China Biomedical Research Conference, - (2009) [E3]
Co-authors Phil Dickson, John Rostas, Kathryn Skelding
2009 Skelding KA, Liao X, Verrills NM, Fluechter L, Dickson PW, Rostas JA, 'CaMKII phosphorylation at T253 alters neuronal growth rates and morphology', Journal of Neurochemistry, Busan, Korea (2009) [E3]
DOI 10.1111/j.1471-4159.2009.06238.x
Co-authors John Rostas, Phil Dickson, Kathryn Skelding
2009 Rostas JA, Skelding KA, Verrills NM, Suzuki PW, Dickson T, 'CaMKII binding partners vary with cell type and phosphorylation state', Journal of Neurochemistry, Busan, Korea (2009) [E3]
DOI 10.1111/j.1471-4159.2009.06238.x
Co-authors John Rostas, Kathryn Skelding
2008 Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Identification of CaMKII binding proteins in brain sensitive to CaMKII phosphorylation state', Proceedings of the Australian Neuroscience Society, Hobart, TAS (2008) [E3]
Co-authors Kathryn Skelding, John Rostas, Phil Dickson, Alistair Sim
2008 Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Development of a novel method for the identification of CaMKII binding proteins', Journal of Neurochemistry, Shanghai, China (2008) [E3]
Co-authors Alistair Sim, Kathryn Skelding, John Rostas, Phil Dickson
2007 Roberts KG, Ashman LK, Sim AT, Verrills NM, 'Regulation of protein phosphatase 2A (PP2A) B subunits by Bcr/Abl: Potential targets for chronic myeloid leukemia', AACR Meeting Abstracts Online (Abstracts of the 98th AACR Annual Meeting), Los Angeles (2007) [E3]
Co-authors Leonie Ashman, Alistair Sim
2007 Roberts KG, Ashman LK, Sim ATR, Verrills NM, 'Altered expression of PP2A regulatory subunits in chronic myelogenous leukemia: Identifying targets for improved therapies', BLOOD, Atlanta, GA (2007)
Co-authors Leonie Ashman
2006 Chang MHY, Engelander J, Verrills NM, Tait AS, Kavallaris M, 'Differential proteomic analysis of low-level anti-microtubule resistance in acute lymphoblastic leukaemia (Poster presentation)', 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (European Journal of Cancer Supplements, Vol 4, no. 12), Prague, Czech Republic (2006) [E3]
Citations Web of Science - 1
2006 Verrills NM, Carpenter HC, Sim AT, 'Disruption of Actin-containing Protein Phosphatase 2A Complexes Regulates Cell Motility in Neuroblastoma Cells', Molecular & Cellular Proteomics, California, USA (2006) [E3]
Co-authors Alistair Sim
2004 Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu M, Yang N, et al., 'Tropomyosin antibodies identify functionally distinct populations of actin filaments', MOLECULAR BIOLOGY OF THE CELL, Washington, DC (2004)
Show 22 more conferences
Edit

Grants and Funding

Summary

Number of grants 59
Total funding $9,240,603

Click on a grant title below to expand the full details for that specific grant.


20154 grants / $751,028

A novel biomarker for luminal B breast cancer$359,577

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Doctor Nikki Verrills, Doctor Kathryn Skelding
Scheme Research Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1400487
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

High resolution fourier transform mass spectrometry platform for the discovery of novel cancer biomarkers and drug targets using label-free and isobaric-tagged approaches for quantitative proteomics.$196,250

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Xu Dong Zhang, Doctor Matt Dun, Professor Jennifer Martin, Professor Hubert Hondermarck, Laureate Professor John Aitken, Doctor Nikki Verrills, Doctor Pradeep Tanwar, Professor Rodney Scott, Professor Maria Kavallaris, Dr Darren Saunders
Scheme Equipment Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500935
Type Of Funding Internal
Category INTE
UON Y

Investigating the in-vitro efficacy of potential anti-CFIDS compounds in c-kit+ myeloid cells$170,201

Funding body: National CFIDS Foundation Inc.

Funding body National CFIDS Foundation Inc.
Project Team Doctor Nikki Verrills
Scheme Research Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1401533
Type Of Funding International - Competitive
Category 3IFA
UON Y

Defining the role of shwachman-bodien diamond syndrome protein (SBDS) in PP2A inhibition in acute myeloid leukaemia (AML)$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Matt Dun, Doctor Nikki Verrills
Scheme Research Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500757
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20148 grants / $872,013

Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia$600,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Doctor Matt Dun, Doctor Nikki Verrills, Associate Professor Martin Larsen
Scheme Early Career Fellowship
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1300952
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

JuLI Stage $71,674

Funding body: NHMRC (National Health & Medical Research Council)

Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia$67,539

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Matt Dun, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1301353
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Targeting a tumour in breast cancer$37,800

Funding body: Pink Frangipani Ball Organising Committee

Funding body Pink Frangipani Ball Organising Committee
Project Team Doctor Nikki Verrills
Scheme Research Project
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1400881
Type Of Funding External
Category EXTE
UON Y

Myr-C310: A new treatment for childhood leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1301349
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Preclinical testing of a novel therapeutic strategy for breast cancer $25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Doctor Kathryn Skelding
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1301439
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Defining the role of shwachman-bodien diamond syndrome protein (SBDS) in PP2A inhibition in acute myeloid leukaemia (AML).$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Matt Dun, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1301442
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Identification of BAALC as a new target for the treatment of acute myeloid leukaemia $20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Kathryn Skelding, Doctor Nikki Verrills
Scheme Near Miss Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1301404
Type Of Funding Internal
Category INTE
UON Y

20134 grants / $414,846

Targeting PP2A to improve the therapeutic efficacy of mutant BRAF inhibitors in melanoma$359,250

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Professor Xu Dong Zhang, Doctor Nikki Verrills, Doctor Chen Chen Jiang
Scheme Research Grant
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1200388
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Targeting BAALC as a new treatment for acute myeloid leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1301348
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Proteomics of Cancer$6,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Matt Dun, Doctor Nikki Verrills, Dr Anoop Enjeti
Scheme Project Grant
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1300054
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20128 grants / $747,800

Activating a tumour suppressor for leukaemia therapy$260,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Doctor Nikki Verrills, Dr Anthony Don, Dr Anoop Enjeti, Associate Professor Jonathan Morris
Scheme Research Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1100512
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Activating a tumour suppressor for leukaemia therapy they receive$100,000

Funding body: Cure Cancer Australia Foundation

Funding body Cure Cancer Australia Foundation
Project Team Doctor Nikki Verrills, Dr Anthony Don, Dr Anoop Enjeti, Associate Professor Jonathan Morris
Scheme Research Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200007
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Microscopic illumination system for advanced fluorescent protein technology$34,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Rick Thorne, Professor Xu Dong Zhang, Conjoint Associate Professor Murray Cairns, Doctor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli, Doctor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck
Scheme Equipment Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1100983
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Role of CaMKII targeting in neuronal susceptibility to excitotoxic cell death$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Emeritus Professor John Rostas, Doctor Neil Spratt, Associate Professor Phillip Dickson, Doctor Nikki Verrills
Scheme Near Miss Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1200673
Type Of Funding Internal
Category INTE
UON Y

Activating a tumour suppressor for leukaemia therapy$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikki Verrills
Scheme Near Miss Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200678
Type Of Funding Internal
Category INTE
UON Y

Regulation of the cell cycle by phosphorylation dependent targeting of CaMKII$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikki Verrills, Doctor Kathryn Skelding, Emeritus Professor John Rostas, Associate Professor Phillip Dickson, Conjoint Professor Keith Jones
Scheme Near Miss Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200679
Type Of Funding Internal
Category INTE
UON Y

FASEB Protein Phosphatases, Snowmass, Colorado USA, 15 - 20 July 2012$1,500

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Nikki Verrills
Scheme Travel Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200803
Type Of Funding Internal
Category INTE
UON Y

20117 grants / $1,770,009

Molecular characterisation of TRAIL-regulated signal transduction pathways and their role in the development, persistence, and exacerbation of allergic airways disease$615,048

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Joerg Mattes, Doctor Nikki Verrills
Scheme Project Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1000314
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Targeting a tumour suppressor, PP2AS for new Leukaemia therapies$600,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Doctor Nikki Verrills
Scheme Early Career Fellowship
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1000861
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Chemical Biology$444,961

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Adam McCluskey, Doctor Warwick Belcher, Doctor Ian Grainge, Professor Christopher Grof, Professor Peter Lewis, Professor Eileen McLaughlin, Doctor Shaun Roman, Conjoint Professor Ray Rose, Doctor Jennette Sakoff, Doctor Nikki Verrills
Scheme Priority Research Centre
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100052
Type Of Funding Internal
Category INTE
UON Y

Preclinical testing of PP2A activating compounds for the treatment of childhood acute lymphoblastic leukaemia$40,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Dr Anthony Don
Scheme Paediatric Oncology Project Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1001001
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Regulation of Breast Cancer Growth by a Novel Phosphorylation-Dependent Targeting Mechanism$35,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Doctor Nikki Verrills, Emeritus Professor John Rostas
Scheme Breast Cancer Project Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1001005
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Targeting PP2A as a Novel Therapeutic Strategy for mutant FLT3* Acute Myeloid Leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Doctor Kyu-Tae Kim, Dr Anoop Enjeti
Scheme Project Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1000990
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

IMPLEN NanoPhotometer pearl$10,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Associate Professor Murray Cairns, Associate Professor Paul Tooney, Professor Alan Brichta, Emeritus Professor John Rostas, Emeritus Professor Patricia Michie, Conjoint Professor Keith Jones, Professor Ulli Schall, Associate Professor Phillip Dickson, Doctor Frederick Walker, Doctor Rick Thorne, Doctor Chris Dayas, Doctor Nikki Verrills, Doctor Janet Holt, Doctor Severine Roselli, Doctor Kathryn Skelding, Doctor Jude Weidenhofer, Associate Professor Liz Milward, Doctor Charles De Bock, Doctor Julie Merriman-Jones, Doctor Jing Qin Wu, Doctor Bing Liu, Mr Dan Johnstone, Ms Belinda Goldie, Doctor Natalie Beveridge
Scheme Equipment Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100030
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20104 grants / $839,000

An Integrated LC-MS-NMR facility for Applications in Proteomics and Organic Chemistry$500,000

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team Professor Adam McCluskey, Laureate Professor John Aitken, Professor Paul Dastoor, Professor Phillip Robinson, Professor Eileen McLaughlin, Emeritus Professor Geoffrey Lawrance, Professor Marcel Maeder, Professor Hugh Dunstan, Doctor Shaun Roman, Professor Rob Atkin, Doctor Clovia Holdsworth, Doctor Mark Baker, Doctor Nikki Verrills, Professor Gottfried Otting, Associate Professor Brett Nixon, Doctor Xiaojing Zhou, Ms Megan Chircop, Doctor Warwick Belcher
Scheme Linkage Infrastructure Equipment & Facilities (LIEF)
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G0190402
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

An Integrated LC-MS-NMR facility for Applications in Proteomics and Organic Chemistry$280,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Adam McCluskey, Laureate Professor John Aitken, Professor Paul Dastoor, Professor Phillip Robinson, Professor Eileen McLaughlin, Emeritus Professor Geoffrey Lawrance, Professor Marcel Maeder, Professor Hugh Dunstan, Doctor Shaun Roman, Professor Rob Atkin, Doctor Clovia Holdsworth, Doctor Mark Baker, Doctor Nikki Verrills, Professor Gottfried Otting, Associate Professor Brett Nixon, Doctor Xiaojing Zhou, Ms Megan Chircop, Doctor Warwick Belcher
Scheme Equipment Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G1000873
Type Of Funding Internal
Category INTE
UON Y

ABI 7500 Real Time PCR System $34,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Rick Thorne, Doctor Nikki Verrills, Conjoint Associate Professor Murray Cairns, Associate Professor Paul Tooney, Doctor Doug Smith, Professor Gordon Burns, Emeritus Professor Leonie Ashman, Conjoint Professor Keith Jones, Doctor Charles De Bock, Doctor Chris Dayas, Doctor Brett Graham, Doctor Martin Horan, Doctor Rebecca Lim, Doctor Severine Roselli, Doctor Larisa Bobrovskaya, Doctor Kathryn Skelding, Doctor Frederick Walker, Doctor Jude Weidenhofer, Associate Professor Philip Bolton, Professor Alan Brichta, Professor Robert Callister, Professor Trevor Day, Associate Professor Phillip Dickson, Professor Manohar Garg, Doctor Phil Jobling, Associate Professor Derek Laver, Associate Professor Eugene Nalivaiko, Emeritus Professor John Rostas
Scheme Equipment Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G1000055
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Epigenetic methylation of PP2A subunit promoters in breast cancer$25,000

Funding body: Hunter Children`s Research Foundation

Funding body Hunter Children`s Research Foundation
Project Team Doctor Nikki Verrills, Doctor Martin Horan
Scheme Research Grant
Role Lead
Funding Start 2010
Funding Finish 2010
GNo G0900148
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20094 grants / $1,161,000

Tetraspanin proteins in prostate cancer progression and prognosis$341,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Emeritus Professor Leonie Ashman, Doctor Nikki Verrills, Conjoint Professor Jim Denham
Scheme Research Grant
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo G0188877
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Confocal Laser Scanning Microscopy for Live Cell Imaging$275,000

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team Conjoint Professor Keith Jones, Professor Eileen McLaughlin, Laureate Professor John Aitken, Conjoint Professor Ray Rose, Emeritus Professor John Patrick, Conjoint Professor Christina Offler, Associate Professor David McCurdy, Emeritus Professor Leonie Ashman, Professor Gordon Burns, Professor Dirk Van Helden, Doctor Nikki Verrills, Associate Professor Brett Nixon, Doctor Shaun Roman, Associate Professor Yong-Ling Ruan, Doctor Rick Thorne, Professor Mike Calford
Scheme Linkage Infrastructure Equipment & Facilities (LIEF)
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo G0189038
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

20085 grants / $1,646,290

HMRI Cancer Research Program - MRSP Infrastructure$1,031,290

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Conjoint Professor Jim Denham, Conjoint Professor Peter Hersey, Professor Gordon Burns, Professor Adam McCluskey, Doctor Nikki Verrills
Scheme NSW MRSP Infrastructure Grant
Role Investigator
Funding Start 2008
Funding Finish 2008
GNo G0188622
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

PP2A: a novel target for leukaemia therapy$300,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Doctor Nikki Verrills, Emeritus Professor Leonie Ashman, Professor Alistair Sim, Associate Professor Danilo Perrotti, Assoc. Prof Timothy Hughes, Dr David Thomas
Scheme Research Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo G0187694
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Functional investigations of novel SET splice isoforms in acute myeloid leukaemia and their potential as a therapeutic target.$270,000

Funding body: Anthony Rothe Memorial Trust

Funding body Anthony Rothe Memorial Trust
Project Team Doctor Nikki Verrills
Scheme Research Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo G0188185
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Novel Alternative Splice Isoforms of the SET Oncogene in Acute Myeloid Leukaemia $25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills
Scheme Project Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo G0188462
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

PP2A: A new target for asthma therapy$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Alistair Sim, Doctor Nikki Verrills, Professor John Scott, Conjoint Professor Peter Wark
Scheme Near Miss Grant
Role Investigator
Funding Start 2008
Funding Finish 2008
GNo G0188395
Type Of Funding Internal
Category INTE
UON Y

20077 grants / $528,630

FACSAria - Fluorescence activated cell sorter$300,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Doctor Nikki Verrills, Emeritus Professor Leonie Ashman, Laureate Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
Scheme Research Infrastructure Grants
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0187666
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

The role of protein phosphatase 2A in breast cancer$75,000

Funding body: Cure Cancer Australia Foundation

Funding body Cure Cancer Australia Foundation
Project Team Doctor Nikki Verrills
Scheme Research Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0186797
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

HMRI Contribution toward FACSAria - Fluorescence activated cell sorter$52,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Emeritus Professor Leonie Ashman, Laureate Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
Scheme Equipment Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0188207
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Differential regulation of human mast cell degranulation by discrete forms of protein phosphatase 2A$50,000

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Professor Alistair Sim, Doctor Nikki Verrills, Laureate Professor Paul Foster, Conjoint Professor Peter Wark, Conjoint Professor Peter Gibson, Dr Gregory Kranias
Scheme Research Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0187247
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

The tumour suppressor gene, PP2A, in breast cancer and its potential as a new target for therapy$29,930

Funding body: Ramaciotti Foundations

Funding body Ramaciotti Foundations
Project Team Doctor Nikki Verrills
Scheme Research Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0188055
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Polymerase Chain Reaction (PCR) machine and Spectrophotometer$20,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Emeritus Professor Leonie Ashman, Professor Alistair Sim, Doctor Nikki Verrills
Scheme Equipment Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0188195
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

American Association of Cancer Research, LA Convention Centre, Los Angeles, USA, 14/4/2007 - 18/4/2007$1,700

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikki Verrills
Scheme Travel Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0187550
Type Of Funding Internal
Category INTE
UON Y

20066 grants / $505,157

The role of protein phosphates in regulating the cytoskeletal dynamics of cancer cells$292,062

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Nikki Verrills
Scheme Training (Postdoctoral) Fellowships - Peter Doherty Biomedical Fellowship (Australia)
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0185634
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Live cell imaging facility$149,100

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Doctor Rick Thorne, Doctor Nikki Verrills, Professor Alistair Sim, Professor Gordon Burns
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo G0186146
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Investigating the functional role of altered expression and point mutations in the tumour suppressor gene PP2A$50,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills
Scheme Special Competitive Research Fund for Early Career Researchers in Cancer
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186082
Type Of Funding Not Known
Category UNKN
UON Y

Novel protein phosphatase interactions in cancer$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Professor Alistair Sim
Scheme Project Grant
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186480
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

High speed computer for a live cell imaging system$3,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Rick Thorne, Professor Gordon Burns, Doctor Nikki Verrills, Professor Alistair Sim
Scheme Equipment Grant
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo G0187279
Type Of Funding Not Known
Category UNKN
UON Y

BioRad Mini-PROTEAN3 Electrophoresis system$995

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Emeritus Professor Leonie Ashman, Associate Professor Phillip Dickson, Emeritus Professor Peter Dunkley, Emeritus Professor John Rostas, Professor Judith Scott, Professor Alistair Sim, Doctor Nikki Verrills
Scheme Equipment Grant
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo G0187280
Type Of Funding Not Known
Category UNKN
UON Y

20051 grants / $2,430

Europhosphatases Conference 2005, 10-14 July 2005$2,430

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikki Verrills
Scheme Travel Grant
Role Lead
Funding Start 2005
Funding Finish 2005
GNo G0185546
Type Of Funding Internal
Category INTE
UON Y

20041 grants / $2,400

12th International Conference on Second Messenger and Phosphoproteins, 3-7 August 2004$2,400

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikki Verrills
Scheme Travel Grant
Role Lead
Funding Start 2004
Funding Finish 2004
GNo G0184543
Type Of Funding Internal
Category INTE
UON Y
Edit

Research Supervision

Current Supervision

Commenced Research Title / Program / Supervisor Type
2015 Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2015 Identifying the Functional Role of SBDS Protein, A Novel Drug Target in Acute Myeloid Leukaemia
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2015 PPP2R2A - A Novel Biomarker and Therapeutic Target for Luminal B Breast Cancer
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2014 To Be Advised
Human Biology, Faculty of Health and Medicine
Co-Supervisor
2007 The role of protein phosphatases in breast cancer
Biochemistry & Cell Biology, University of Newcastle
Co-Supervisor
2006 Role of PP2A in cancer
Biochemistry & Cell Biology, University of Newcastle
Co-Supervisor
2006 PP2A in mast cell function
Biochemistry & Cell Biology, University of Newcastle
Co-Supervisor

Past Supervision

Year Research Title / Program / Supervisor Type
2014 Targeting PP2A Activation as a Novel Therapeutic Strategy for Receptor Tyrosine Kinase Driven Leukemia
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2012 The Role of Protein Phosphatase 2A as a Tumour Suppressor in Breast Cancer
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2011 Regulation of Mast Cell Degranulation by Protein Phosphatase 2A
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2010 Regulation of the Tumour Suppressor PP2A by Oncogenic Tyrosine Kinases
Medical Science, Faculty of Health and Medicine
Principal Supervisor
Edit

News

Xu Dong Zhang

$1m for visionary cancer researchers

May 1, 2015

Two of the University of Newcastle's leading researchers have been awarded more than $1m in grants to focus on discovering new methods of curbing and treating cancer.

Cancer Council NSW research grant success

$1 million in Cancer Council NSW project grants

January 12, 2015

Two University of Newcastle (UON) cancer researchers from the School of Biomedical Sciences and Pharmacy in the Faculty of Health and Medicine have been awarded more than $1 million in Cancer Council NSW project grants for 2015.

Dr Nikki Verrills

Position

Senior Lecturer
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Medical Biochemistry

Contact Details

Email nikki.verrills@newcastle.edu.au
Phone (02) 4921 5619
Fax (02) 4921 6903

Office

Room LS3-46
Building Life Sciences
Location Callaghan
University Drive
Callaghan, NSW 2308
Australia
Edit